Payment overview · 2025
General Payments
$1,560.46
97 reported records · 25 companies
Healthcare provider profile · identity verified
Scott Mcright, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SHREVEPORT, LA · NPI 1568605004
Verified facts
What the public records show
CMS Open Payments records show Scott Mcright, MD received $1,560.46 in general payments during 2025 across 97 reported records.
PFIZER INC. accounted for 11.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $172.75 | 11.1% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $151.70 | 9.7% | 16 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $147.76 | 9.5% | 7 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $137.97 | 8.8% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $112.63 | 7.2% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $80.99 | 5.2% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $65.29 | 4.2% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $62.07 | 4.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $60.31 | 3.9% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.36 | 3.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.70 | 3.6% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $54.47 | 3.5% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $51.14 | 3.3% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $43.85 | 2.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $43.69 | 2.8% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $41.86 | 2.7% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $40.89 | 2.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $40.06 | 2.6% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.28 | 1.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.83 | 1.7% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $24.12 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.49 | 1.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.94 | 1.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.83 | 0.9% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $13.48 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,560.46 | 97 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $151.70 | 16 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $151.70 | 16 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $147.76 | 7 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $137.97 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $128.86 | 9 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $114.33 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $104.00 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $80.99 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $80.99 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $65.29 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $62.07 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $58.60 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $55.70 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $54.47 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $54.03 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $51.14 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $43.89 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $43.89 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $43.89 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $43.85 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $40.06 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $39.09 | 2 | 2025 |
Source payment records
|
|||||
| KOSELUGO Normalized: koselugo |
Drug | Alexion Pharmaceuticals, Inc. | $28.28 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.83 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $24.12 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.92 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 130 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 114 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 131 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
83 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
130 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
114 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
131 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
130 | 29 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 569 | 169 |
| Amlodipine Besylate | Amlodipine Besylate | 509 | 142 |
| Levothyroxine Sodium | Levothyroxine Sodium | 487 | 137 |
| Alprazolam | Alprazolam | 368 | 85 |
| Losartan Potassium | Losartan Potassium | 349 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 316 | 98 |
| Lisinopril | Lisinopril | 300 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 239 | 65 |
| Metformin Hcl | Metformin Hcl | 234 | 66 |
| Omeprazole | Omeprazole | 231 | 70 |
| Duloxetine Hcl | Duloxetine Hcl | 222 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 204 | 64 |
| Quetiapine Fumarate | Quetiapine Fumarate | 202 | 39 |
| Prednisone | Prednisone | 195 | 146 |
| Glipizide | Glipizide | 190 | 51 |
| Meloxicam | Meloxicam | 184 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 180 | 58 |
| Gabapentin | Gabapentin | 175 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 171 | 34 |
| Simvastatin | Simvastatin | 163 | 53 |
| Potassium Chloride | Potassium Chloride | 158 | 46 |
| Furosemide | Furosemide | 152 | 54 |
| Sertraline Hcl | Sertraline Hcl | 146 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 139 | 35 |
| Trazodone Hcl | Trazodone Hcl | 132 | 39 |
| Ozempic | Semaglutide | 131 | 32 |
| Eliquis | Apixaban | 130 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 117 | 36 |
| Montelukast Sodium | Montelukast Sodium | 115 | 32 |
| Mounjaro | Tirzepatide | 114 | 20 |
| Temazepam | Temazepam | 114 | 32 |
| Allopurinol | Allopurinol | 103 | 32 |
| Ezetimibe | Ezetimibe | 101 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 98 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 25 |
| Levofloxacin | Levofloxacin | 95 | 83 |
| Tramadol Hcl | Tramadol Hcl | 95 | 27 |
| Carvedilol | Carvedilol | 91 | 31 |
| Synthroid | Levothyroxine Sodium | 83 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 22 |
| Finasteride | Finasteride | 79 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 29 |
| Clonazepam | Clonazepam | 74 | 13 |
| Atenolol | Atenolol | 71 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 30 |
| Celecoxib | Celecoxib | 66 | 25 |
| Donepezil Hcl | Donepezil Hcl | 66 | 15 |
| Azithromycin | Azithromycin | 64 | 54 |
| Diazepam | Diazepam | 64 | 27 |
| Olanzapine | Olanzapine | 63 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 12 |
| Spironolactone | Spironolactone | 60 | 19 |
| Fenofibrate | Fenofibrate | 56 | 17 |
| Glipizide Er | Glipizide | 55 | 16 |
| Januvia | Sitagliptin Phosphate | 54 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 46 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 49 |
| Mirtazapine | Mirtazapine | 49 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 48 | 14 |
| Metformin Hcl Er | Metformin Hcl | 48 | 13 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | 28 |
| Nifedipine Er | Nifedipine | 43 | 15 |
| Buspirone Hcl | Buspirone Hcl | 42 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 37 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 18 |
| Primidone | Primidone | 41 | 14 |
| Pregabalin | Pregabalin | 39 | 11 |
| Ramipril | Ramipril | 39 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 33 |
| Sucralfate | Sucralfate | 38 | 15 |
| Lorazepam | Lorazepam | 37 | 11 |
| Famotidine | Famotidine | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 22 |
| Ondansetron Odt | Ondansetron | 33 | 19 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | suppressed |
| Digoxin | Digoxin | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | 13 |
| Prazosin Hcl | Prazosin Hcl | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 31 | suppressed |
| Estradiol | Estradiol | 31 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 27 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 14 |
| Trulicity | Dulaglutide | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | 14 |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Nystatin | Nystatin | 18 | 13 |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Acetazolamide | Acetazolamide | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 13 |
| Propafenone Hcl | Propafenone Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,560.46 · 97 records | PFIZER INC. | ABRYSVO, ACCRUFER, AIRSUPRA, Auvelity, CAMZYOS, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, EVENITY, GEMTESA, GVOKE HYPOPEN, INJECTAFER, JARDIANCE, KOSELUGO, Korlym, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SHINGRIX, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error